NSTEMI (Non-ST-segment elevation myocardial infarction)

Find all the latest content on NSTEMI published on this website.

NSTEMI is considered one of the leading causes of morbidity and mortality and its definition and treatment remains challenging requiring specific, adapted responses. Understanding different biomarkers, becoming aware of emerging new agents used in adjunctive pharmacotherapy, keeping abreast of advances in imaging techniques as well as the use of invasive imaging and functional assessment is critical. Tools, devices and techniques, and complications such as different types of vascular access or bleeding risks, can also be found here…

Filtered By
NSTEMI

194 results

Interesting scenarios in coronary interventions

Learn more from this selection of challenging cases on PCI in pregnancy, recurrent rest angina in a post CABG patient and complications due to infective endocarditis.

Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes

22 Mar 2018

Dejan Milasinovic

Reviewer

Dejan Milasinovic

Cardio Poll: How will the SMART DATE study results impact your clinical practice?

The recent SMART-DATE trial ultimately showed non-inferiority for MACE of 6 months vs. 12 months DAPT in ACS patients treated with current generation DES. Yet, myocardial infarction (a secondary endpoint) was increased by 1% in the short DAPT group and no difference for stent thrombosis and major bleeding was observed between the two treatment arms.

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

15 Mar 2018

Daniele Giacoppo

Reviewer

Daniele Giacoppo

SMART-DATE: 6-month versus 12-month or longer DAPT after PCI in patients with acute coronary syndrome - a randomised, open-label, non-inferiority trial

13 Mar 2018

The SMART DATE trial presented at ACC1.8 and published simultaneously in the Lancet is yet another trial evaluating the duration of antiplatelet therapy in patients with acute coronary syndrome (ACS).

SECURE PCI: Loading Doses of Atorvastatin versus Placebo in Patients with ACS and planned revascularisation

12 Mar 2018

SECURE PCI evaluated if high dose of atorvastatin used before and after PCI might reduce cardiovascular events compared to placebo.

ODYSSEY Outcomes: Cardiovascular outcomes with alirocumab after acute coronary syndrome

11 Mar 2018

Patients with ACS experience adverse events despite guideline recommended care. This reiterates the need for additional therapy to address this problem in addition to standard care. Alirocumab in ODYSSEY Outcomes, the first trial conducted exclusively in ACS patients, provides promise with 15% reduction in MACE events.

Editor's picks: impactful articles in interventional cardiology

Struggling to keep up with the mass of scientific information in interventional cardiology? On this page you will find a selection of recent articles published in major journals in the field - use it to guide your reading!

Randomised Trials in prevention contrast-induced nephropathy

On this page you will find a list of randomised trials in prevention contrast-induced nephropathy published in some of the world's top cardiology and interventional cardiology journals.

Randomised Trials in FFR and PCI

On this page you will find a list of randomised trials in FFR and PCI published in some of the world's top cardiology and interventional cardiology journals.